Escalier Biosciences is developing both topical and oral RORγt inverse agonists for the treatment of a broad spectrum of psoriasis patients – from the underserved mild-to-moderate patients that would benefit from a safe and effective topical RORγt therapeutic to the more moderate-to-severe patients that would benefit from a safe and effective oral RORγt drug in lieu of injectable biologic therapies targeting IL-17 and IL-23.

Biotechnology

Education

Escalier Biosciences

Raju Mohan

Chris Krueger

John Nuss

The Advisory Board at Escalier Biosciences provides strategic guidance and expertise to support the development of innovative RORγt inverse agonists for psoriasis treatment. Composed of industry experts and thought leaders, the team offers insights on clinical trials, regulatory pathways, and market needs, ensuring that the company's therapies effectively address the needs of both mild-to-moderate and moderate-to-severe psoriasis patients.

Advisory Board

About

Team members

Other teams at Escalier Biosciences

Leadership Team